Results 31 to 40 of about 9,286 (149)

Postnatally Acquired Cytomegalovirus Infection in Extremely Premature Infants: A Prospective Observational Cohort Study

Acta Paediatrica, EarlyView.
ABSTRACT Aim Postnatally acquired cytomegalovirus (pCMV) infection may cause severe disease in extremely preterm infants, but its clinical significance remains uncertain. We investigated the incidence, timing, disease burden, and diagnostic performance of saliva screening. Method In this prospective cohort study, infants born at < 28 weeks of gestation
Sara Krøis Holm, Lise Aunsholt, Porntiva Poorisirak, Alex Christian Yde Nielsen, Rune Micha Pedersen, Bo Mølholm Hansen, Anne Mette Plomgaard, Karina Kwi Im Jordan, Hristo Stanchev, Maren Rytter, Tatjana Zaharov, Sven Bonato, Kia Schultz Dungu, Anja Poulsen, Susanne Søndergaard Kappel, Ulrikka Nygaard, Stine Lund   +16 more
wiley   +1 more source

Long‐term results of brentuximab vedotin and bendamustine for first‐line treatment of Hodgkin lymphoma in the elderly (HALO trial)

British Journal of Haematology, EarlyView.
Summary The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well‐tolerated, effective drugs in relapsing HL, but no data exist on Be‐BV frontline treatment in eHL.
Andrea Gallamini, Simonetta Viviani, Davide Rapezzi, Caterina Patti, Pierre Feugier, Alessandro Rambaldi, Fontanet Bijou, Anna Borra, Cécile Borel, Tanguy Pace‐Loscos, Renaud Schiappa, Stephane Chauvie, Colin Debaigt, Anna Guidetti, Olivier Humbert, Jean‐Marc Schiano De Colella   +15 more
wiley   +1 more source

A case of successful contribution of therapeutic drug monitoring of valganciclovir as the prophylaxis against cytomegalovirus infection in a lung transplant recipient

Journal of Pharmaceutical Health Care and Sciences
Background Ganciclovir and its prodrug, valganciclovir, are first-line agents for cytomegalovirus infection prophylaxis after lung transplantation. Although valganciclovir prophylaxis is known to result in severe leukopenia as an adverse effect, dosage ...
Yoshiki Katada, Keisuke Umemura, Shunsaku Nakagawa, Yurie Katsube, Masahiro Tsuda, Satona Tanaka, Hiroshi Date, Miki Nagao, Tomohiro Terada   +8 more
doaj   +1 more source

Pediatric Dosing of Ganciclovir and Valganciclovir: How Model‐Based Simulations Can Prevent Underexposure and Potential Treatment Failure

CPT: Pharmacometrics & Systems Pharmacology, 2019
Intravenous ganciclovir and oral valganciclovir are effective in the prevention and treatment of pediatric cytomegalovirus (CMV) infection but various dosing regimens are used in medical practice.
Karin Jorga, Bruno Reigner, Clarisse Chavanne, Giuseppe Alvaro, Nicolas Frey   +4 more
doaj   +1 more source

Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results

Scientific Reports, 2021
We evaluated the therapeutic outcome of intravitreal injection (IVI) of ganciclovir with/without oral valganciclovir for cytomegalovirus (CMV) anterior segment infection.
Yu-Chun Cheng, Eugene Yu-Chuan Kang, Yih-Shiou Hwang, Ching-Hsi Hsiao   +3 more
doaj   +1 more source

ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand

Internal Medicine Journal, EarlyView.
Abstract Background Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients.
Andrea Henden, Lynette Chee, Julia Clark, Rachel Conyers, Julian Cooney, Richard Doocey, David Gottlieb, Tim Prestidge, Madeleine Powys, Philip Selby, Gaurav Sutrave, Eric Wong, Michelle K. Yong, Nada Hamad   +13 more
wiley   +1 more source

Valganciclovir [PDF]

Reactions Weekly, 2021
  +8 more sources

Long-term results of oral valganciclovir for treatment of anterior segment inflammation secondary to cytomegalovirus infection

Clinical Ophthalmology, 2012
Victoria WY Wong, Carmen KM Chan, Dexter YL Leung, Timothy YY LaiDepartment of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Hong Kong, People&#39;s Republic of ChinaBackground: The purpose of this ...
Wong VW, Chan CK, Leung DY, Lai TY
doaj  

The Association of Pretransplant CD4 Count With Post‐Kidney Transplant Infectious Outcomes Among Persons With HIV

Transplant Infectious Disease, EarlyView.
In this multi‐center study comparing persons with HIV with pre‐kidney transplant CD4 < 350 cells/µL to those with ≥ 350 cells/µL, we found no difference in relative risk of infection in the first year‐post kidney transplant, 5‐year graft survival, and 5‐year overall survival.
Rebecca H. Burns, Sara Booth, Christin Rogers Marks, Christine M. Durand, Jonathan Hand, Maheen Z. Abidi, Maricar Malinis, Brittany Barnaba, Martha Pavlakis, Douglas Krakower, Carolyn D. Alonso, Audrey Le‐Mahajan   +11 more
wiley   +1 more source

Cytomegalovirus–Cell‐Mediated Immunity Assays for the Prevention and Management of Cytomegalovirus in Transplant Recipients and Patients Receiving Cellular Therapies

Transplant Infectious Disease, EarlyView.
This review summarizes the emerging role of CMV‐specific cell‐mediated immunity assays in CMV risk prediction and individualized prevention strategies across SOT, HCT, and CAR‐T settings. ABSTRACT CMV cell–mediated immunity (CMV–CMI) testing has emerged as a promising tool to refine CMV risk stratification and inform prevention strategies in transplant
Elisa Ruiz‐Arabi, Madeleine R. Heldman, Laurie D. Snyder, Oriol Manuel, Eleftheria Kampouri   +4 more
wiley   +1 more source